GlassScriptPhysician profile
Michael Joseph Trybula
NPI 1548502958
$2,304.77
in general payments reported to CMS, 2019-2025
18 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $48.94 · 2021: $91.33 · 2022: $378 · 2023: $413 · 2024: $441 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $468.49 | 2022-2025 | |
| Amgen INC. | $379.98 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $286.99 | 2022-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $276.81 | 2019-2025 | |
| Heartflow, INC. | $254.97 | 2023-2025 | Ffrct |
| Abbott Laboratories | $152.78 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Kowa Pharmaceuticals America, INC. | $131.61 | 2019 | |
| Medtronic, INC. | $63.46 | 2023 | O-Arm |
| Novo Nordisk INC | $63.05 | 2024 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $32.18 | 2022-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $31.19 | 2024 | Arcalyst |
| Cvrx, INC. | $28.68 | 2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $24.49 | 2025 | Praluent, Evkeeza |
| Edwards Lifesciences Corporation | $22.16 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.11 | 2022 | |
| Tactile Systems Technology INC | $17.93 | 2023 | Flexitouch Plus, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trybula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.